Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Agulnik

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Annales Paediatrici. International Review of Pediatrics|March 19, 2010
Primary, purulent pyocyaneus meningitis in a young childM AGULNIK
Current Oncology Reports|April 27, 2012
Advances in adjuvant therapy of gastrointestinal stromal tumorsK Adekola, M Agulnik
Current Medicinal Chemistry. Anti-Cancer Agents|December 8, 2004
An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agentsM Agulnik, L L Siu
British Journal of Cancer|March 10, 2005
State-of-the-art management of nasopharyngeal carcinoma: current and future directionsM Agulnik, L L Siu
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|February 24, 2001
Resource utilization for peritoneal catheter placementM Agulnik, D J Hirsch
Oral Oncology|April 26, 2011
Oral complications of targeted cancer therapies: a narrative literature reviewA L Watters, J B Epstein, M Agulnik
American Journal of Clinical Oncology|March 10, 2001
Malignant lymphoma of mucosa-associated lymphoid tissue of the lacrimal gland: case report and review of literatureM Agulnik, R Tsang, M A Baker, et al.
Journal of Chemotherapy (Florence, Italy)|June 1, 2005
Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancerM Agulnik, E N Rhee, M Yao, et al.
Journal of the National Cancer Institute|December 17, 2009
Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapyR E Eilers, M Gandhi, J D Patel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2012
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomasM Agulnik, J L Yarber, S H Okuno, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Annales Paediatrici. International Review of Pediatrics|March 19, 2010
Primary, purulent pyocyaneus meningitis in a young childM AGULNIK
Current Oncology Reports|April 27, 2012
Advances in adjuvant therapy of gastrointestinal stromal tumorsK Adekola, M Agulnik
Current Medicinal Chemistry. Anti-Cancer Agents|December 8, 2004
An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agentsM Agulnik, L L Siu
British Journal of Cancer|March 10, 2005
State-of-the-art management of nasopharyngeal carcinoma: current and future directionsM Agulnik, L L Siu
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|February 24, 2001
Resource utilization for peritoneal catheter placementM Agulnik, D J Hirsch
Oral Oncology|April 26, 2011
Oral complications of targeted cancer therapies: a narrative literature reviewA L Watters, J B Epstein, M Agulnik
American Journal of Clinical Oncology|March 10, 2001
Malignant lymphoma of mucosa-associated lymphoid tissue of the lacrimal gland: case report and review of literatureM Agulnik, R Tsang, M A Baker, et al.
Journal of Chemotherapy (Florence, Italy)|June 1, 2005
Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancerM Agulnik, E N Rhee, M Yao, et al.
Journal of the National Cancer Institute|December 17, 2009
Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapyR E Eilers, M Gandhi, J D Patel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2012
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomasM Agulnik, J L Yarber, S H Okuno, et al.
Pageof 2